Is Medline Inc (MDLN) a risky stock?
As of July 21, 2026, Clavix grades Medline Inc (MDLN) B for risk, a composite score of 71 out of 100 on an A+ to F scale, which puts MDLN in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind MDLN's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how MDLN scores on each, as of July 21, 2026.
What's moving MDLN's risk right now
Company-specific signals Clavix flags behind MDLN's current grade, drawn from recent news and filings as of July 21, 2026.
The successful integration of Coloplast's skin care business strengthens Medline's vertical manufacturing capabilities and expands its Remedy skin health portfolio, supporting com…
The expansion strengthens Medline's distribution capacity in a key market and signals continued capital deployment toward supply chain hardening, which supports revenue growth and…
The expansion signals Medline's continued capital deployment to scale distribution capacity, likely supporting revenue growth in California while requiring meaningful near-term ca…
What a B grade means
On the Clavix A+ to F scale, MDLN's composite of 71 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell MDLN or any security. Grades are risk indicators, not predictions of return. Data may be delayed.